

Auswahl von Publikationen der Sektion Mukoviszidose

Stass H, Delesen H, Nagelschmitz J, Staab D.

Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study.

J Aerosol Med Pulm Drug Deliv. 2015 Apr;28 (2):106-15. doi: 10.1089/jamp.2013.1056. Epub 2014 Jul 22.

Stahl K, Steinkamp G, Ullrich G, Schulz W, van Koningsbruggen-Rietschel S, Heuer HE, Ellemunter H, Schwarz C.

Patient experience in cystic fibrosis care: Development of a disease-specific questionnaire.

Chronic Illn. 2015 Jun;11(2):108-25. doi: 10.1177/1742395314542051. Epub 2014 Jun 27.

Steinkamp G, Stahl K, Ellemunter H, Heuer E, van Koningsbruggen-Rietschel S, Busche M, Bremer W, Schwarz C; Patient Experience Working Group..

Cystic fibrosis (CF) care through the patients' eyes - a nationwide survey on experience and satisfaction with services using a disease-specific questionnaire.

Respir Med. 2015 Jan;109(1):79-87. doi: 10.1016/j.rmed.2014.11.007. Epub 2014 Dec 6.

Sedlacek L, Graf B, Schwarz C, Albert F, Peter S, Würstl B, Wagner S, Klotz M, Becker A, Haase G, Laniado G, Kahl B, Suerbaum S, Seibold M, Tintelnot K.

Prevalence of *Scenedosporium* species and *Lomentospora prolificans* in patients with cystic fibrosis in a multicenter trial by use of a selective medium.

J Cyst Fibros. 2015 Mar;14(2):237-41. doi: 10.1016/j.jcf.2014.12.014. Epub 2015 Jan 13.

Dorkin HL, Staab D, Operschall E, Alder J, Criollo M.

Ciprofloxacin DPI: a randomised, placebo-controlled, phase IIb efficacy and safety study on cystic fibrosis.

BMJ Open Respir Res. 2015 Dec 2;2(1):e000100. doi: 10.1136/bmjresp-2015-000100. eCollection 2015.

van Koningsbruggen-Rietschel S, Heuer HE, Merkel N, Posselt HG, Staab D, Sieder C, Ziegler J, Krippner F, Rietschel E.

Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation of tobramycin in cystic fibrosis patients.

J Antimicrob Chemother. 2016 Mar;71(3):711-7. doi: 10.1093/jac/dkv399. Epub 2015 Nov 30.

Scheuing N, Holl RW, Dockter G, Hermann JM, Junge S, Koerner-Rettberg C, Naehrlich L, Smaczny C, Staab D, Thalhammer G, van Koningsbruggen-Rietschel S, Ballmann M. High variability in oral glucose tolerance among 1,128 patients with cystic fibrosis: a multicenter screening study.

PLoS One. 2014 Nov 13;9(11):e112578. doi: 10.1371/journal.pone.0112578. eCollection 2014.

Roehmel JF, Tintelnot K, Bernhardt A, Seibold M, Staab D, Schwarz C.

Arxula adenivorans causing invasive pulmonary mycosis and fungaemia in cystic fibrosis.

Lancet. 2015 Apr 11;385(9976):1476. doi: 10.1016/S0140-6736(15)60260-4.

Schwarz C, Staab D.

Cystic fibrosis and associated complications

Internist (Berl). 2015 Mar;56(3):263-74. doi: 10.1007/s00108-014-3646-z. German.

Roehmel JF, Schwarz C, Mehl A, Stock P, Staab D.

Hypersensitivity to antibiotics in patients with cystic fibrosis.

J Cyst Fibros. 2014 Mar;13(2):205-11. doi: 10.1016/j.jcf.2013.10.002. Epub 2013 Oct 26.

Renz DM, Scholz O, Böttcher J, Maurer MH, Denecke T, Schwarz C, Pfeil A, Streitparth F, Huppertz A, Mehl A, Poellinger A, Staab D, Hamm B, Mentzel HJ.

Comparison between magnetic resonance imaging and computed tomography of the lung in patients with cystic fibrosis with regard to clinical, laboratory, and pulmonary functional parameters.

Invest Radiol. 2015 Oct;50(10):733-42. doi: 10.1097/RLI.000000000000178.